KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for TherapeuticsMD (TXMD) over the last 5 years, with Sep 2025 value amounting to $10.4 million.

  • TherapeuticsMD's Total Non-Current Liabilities fell 11.89% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 11.89%. This contributed to the annual value of $10.7 million for FY2024, which is 20.01% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Total Non-Current Liabilities is $10.4 million, which was down 0.23% from $10.4 million recorded in Q2 2025.
  • TherapeuticsMD's Total Non-Current Liabilities' 5-year high stood at $272.7 million during Q1 2022, with a 5-year trough of $10.4 million in Q3 2025.
  • Over the past 3 years, TherapeuticsMD's median Total Non-Current Liabilities value was $11.8 million (recorded in 2024), while the average stood at $14.6 million.
  • Per our database at Business Quant, TherapeuticsMD's Total Non-Current Liabilities rose by 8.23% in 2021 and then slumped by 90.29% in 2023.
  • Over the past 5 years, TherapeuticsMD's Total Non-Current Liabilities (Quarterly) stood at $261.0 million in 2021, then tumbled by 79.23% to $54.2 million in 2022, then tumbled by 75.31% to $13.4 million in 2023, then fell by 20.01% to $10.7 million in 2024, then decreased by 11.89% to $10.4 million in 2025.
  • Its Total Non-Current Liabilities was $10.4 million in Q3 2025, compared to $10.4 million in Q2 2025 and $10.7 million in Q1 2025.